<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367146</url>
  </required_header>
  <id_info>
    <org_study_id>MHH3474MMF</org_study_id>
    <nct_id>NCT00367146</nct_id>
  </id_info>
  <brief_title>MMF After Pediatric Liver Transplantation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of CNIs (CSA or FK) as primary immunosuppressive drugs after pediatric liver
      transplantation is one of the main causes of chronic kidney disease in these patients in the
      long term.

      The study objective is the evaluation of safety of a modification in immunosuppression from a
      dual-immunosuppression (CSA or FK plus steroids) to a triple immunosuppression (MMF plus CSA
      (reduced dosage) plus steroids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of a triple immunosuppression (MMF/CSA/Steroids)regarding the number of acute rejections</measure>
    <time_frame>1, 3, 6, 9, 12, 24 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of chronic kidney disease</measure>
    <time_frame>12, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of infections</measure>
    <time_frame>1, 3, 6, 9, 12, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of ptld (post transplant lymphoproliferative disease)</measure>
    <time_frame>1, 3, 6, 9, 12, 24 month</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Chronic Kidney Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMF</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients after pediatric liver transplantation

          -  no acute rejections for the last half year

        Exclusion Criteria:

          -  concomitant malign disease (e.g. ptld)

          -  neutropenia (granulocytes &lt;1000/Âµl)

          -  systemic infection

          -  thrombopenia (&lt;80/nl)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Melter, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hannover medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2006</study_first_submitted>
  <study_first_submitted_qc>August 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2006</study_first_posted>
  <last_update_submitted>May 19, 2011</last_update_submitted>
  <last_update_submitted_qc>May 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2011</last_update_posted>
  <keyword>liver transplantation</keyword>
  <keyword>children</keyword>
  <keyword>immunosuppression</keyword>
  <keyword>mycophenolatmofetil</keyword>
  <keyword>calcineurin inhibitor</keyword>
  <keyword>kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

